Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Population Genomic Screening Programs Market Report 2026 | Capitalize on 14.6% CAGR to 2030 as Illumina, Roche, Thermo Fisher and Natera Scale AI and Precision Medicine

globenewswire.com
ILMN Illumina is mentioned as a key player in the growing population genomic screening market, which is benefiting from advances in sequencing technologies and AI. The company is expected to capitalize on this growth. TMO Thermo Fisher Scientific is listed as a significant company in the population genomic screening market. The market's growth, fueled by technological advancements and AI, is a positive indicator for Thermo Fisher. NTRS Natera is highlighted for its strategic acquisition of Invitae, which expands its capabilities in prenatal testing and carrier screening. This move positions Natera to capitalize on the growing demand for genomic services.

Global Population Genomic Screening Programs Market Report 2026 | Capitalize on 14.6% CAGR to 2030 as Illumina, Roche, Thermo Fisher and Natera Scale AI and Precision Medicine Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Population Genomic Screening Programs Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global population genomic screening programs market is experiencing rapid growth, supported by advances in sequencing technologies, greater awareness of hereditary diseases and expanding public health initiatives. The market is projected to increase from $3.91 billion in 2025 to $4.47 billion in 2026, representing a compound annual growth rate (CAGR) of 14.3%.

Growth during the historical period was driven by the implementation of newborn screening programs, improvements in healthcare infrastructure, increased government investment and wider access to genomic technologies. These developments have enabled healthcare systems to identify genetic risks earlier and incorporate genomic insights into clinical decision-making and preventive care.

The population genomic screening programs market is forecast to reach $7.7 billion by 2030, expanding at a CAGR of 14.6%. Key growth drivers include the expansion of adult and carrier screening programs, increasing demand for personalized medicine, investment in population-scale genomic research and the adoption of artificial intelligence for genomic interpretation. Integration with digital health platforms and electronic health records is also expected to improve the accessibility and clinical value of genomic screening.

Personalized medicine remains a significant catalyst for market expansion. Advances in genomics and molecular diagnostics are helping clinicians identify genetic differences, select targeted therapies and reduce the risk of adverse treatment effects. Population genomic screening programs support this approach by detecting disease-associated variants across large and diverse populations, facilitating earlier interventions, patient stratification and tailored prevention strategies.

Momentum in personalized medicine is reflected in the growing number of targeted therapies receiving regulatory approval. In 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, compared with six approvals in 2022, according to the Personalized Medicine Coalition. This increase highlights the growing role of genomic information in treatment development and patient care.

Innovation in hereditary risk assessment is another important population genomic screening market trend. Providers are developing solutions that identify genetic predispositions earlier, support preventive healthcare planning and improve long-term outcomes. In November 2023, Helix OpCo partnered with Cone Health to launch a population genomics initiative supporting precision medicine in North Carolina. The program uses an end-to-end genomics platform to generate actionable clinical insights, enable earlier interventions and advance community health and health equity across multiple counties.

Strategic acquisitions are also strengthening market capabilities. In August 2024, Natera completed its acquisition of Invitae for an undisclosed amount. The transaction is intended to expand Natera's capabilities in non-invasive prenatal testing and carrier screening while extending genomic services to more patients and healthcare providers.

Leading market trends include population-wide genetic risk assessment, artificial intelligence-driven variant interpretation, personalized preventive health programs and stronger data security and privacy compliance. Screening initiatives increasingly cover newborn screening, adult screening, carrier screening and pharmacogenomics. Applications span rare disease detection, cancer risk assessment, chronic disease prediction and treatment selection, with hospitals, diagnostic laboratories, research institutes and government agencies among the principal users.

North America was the largest region in the population genomic screening programs market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries included are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.

Markets Covered:

1) By Program Type: Newborn Screening; Adult Screening; Carrier Screening; Pharmacogenomics; Other Program Types

2) By Program Model: National Screening Programs; Regional Screening Programs; Institution Based Screening; Direct To Consumer Screening

3) By Technology: Next Generation Sequencing; Microarray; Polymerase Chain Reaction; Other Technologies

4) By Application: Rare Disease Detection; Cancer Risk Assessment; Pharmacogenomics; Chronic Disease Prediction; Other Applications

5) By End-User: Hospitals; Research Institutes; Government Agencies; Diagnostic Laboratories; Other End-Users

Subsegments:

1) By Newborn Screening: Rare Disease Screening; Metabolic Disorder Screening; Immunodeficiency Disorder Screening; Neurological Disorder Screening; Endocrine Disorder Screening

2) By Adult Screening: Hereditary Cancer Risk Screening; Cardiovascular Genetic Risk Screening; Neurodegenerative Disease Risk Screening; Preventive Health Risk Screening; Late Onset Genetic Disorder Screening

3) By Carrier Screening: Preconception Carrier Screening; Prenatal Carrier Screening; Expanded Carrier Screening; Recessive Disorder Carrier Screening; Population Based Carrier Screening

4) By Pharmacogenomics: Drug Response Prediction Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Testing; Therapeutic Selection Testing; Medication Safety Testing

5) By Other Program Types: Polygenic Risk Assessment Programs; Predictive Genomic Health Programs; Preventive Genomic Screening Programs; Population Risk Stratification Programs; Research Based Genomic Screening Programs

Time Series:

Five years historic and ten years forecast.

Data:

Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation:

Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes:

Companies Featured

The companies featured in this Population Genomic Screening Programs market report include:

For more information about this report visit https://www.researchandmarkets.com/r/ybrg1p

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.